MANCHESTER, England & DUBLIN, August 23, 2022–(BUSINESS WIRE)–Terebellum, the Ireland and UK-based subsidiary of AscellaHealth, a global healthcare and specialty pharmacy solutions company and a member of the AscellaHealth Family of Companies, announces its international positioning with strategic planning sessions for 2023 in Manchester, UK and Dublin, Ireland to evaluate ongoing synergies with pharmaceutical company partners and plan management training programmes. Working with The Brooks Group, an organization that uses real science and real insights to deliver training that leads to increased sales and revenue, Terebellum’s leadership team has laid the foundation for a robust business.
Craig Caceci, executive vice president and managing director, Terebellum, said: “We are bringing our passionate commitment to the European market to provide innovative programs and services designed to optimize clinical outcomes and quality of life for patients with complex chronic conditions or rare diseases. By partnering with multiple pharmaceutical manufacturers to help them realize a product’s full potential, we provide a full complement of integrated solutions, including strategic insights for early stage products, market access expertise, logistics distribution and supply chain fulfillment and unique pharmaceutical financial services.”
Pointing to Terebellum’s commitment to always putting patients first, Caceci added: “This value statement transcends every aspect of our consultative approach to provide end-to-end solutions that result in better patient outcomes. This level of commitment sets apart our organization and contributes to our growing standing among pharmaceutical companies around the world that benefit from working with a single source to manage all program and drug launch milestones.”
John Bruton, former Taoiseach of Ireland and a non-executive resident director and board member, Terebellum, is instrumental in the planning sessions, saying: “Many people suffer from conditions that are so rare that treatments have not been developed or are unaffordable. become aware over many years. Terebellum is trying to solve this problem by working with patients, their families, pharmaceutical manufacturers and insurers.”
Terebellum built account management and sales teams to proactively support customers and turned to Ryan Evans, president of The Brooks Group, for training and education programs.
“It’s exciting to partner with these healthcare leaders at Terebellum, who are bringing thoughtful strategies and solutions to the international market for the unique populations of rare diseases,” Evans said. “Energized with this training, Terebellum’s marketing executives will be highly responsive to manufacturers’ expectations as they strive to meet the diverse, specialized needs of patients.”
Terebellum is an Ireland and UK based subsidiary of AscellaHealth representing our global presence across Europe. Our industry-leading group procurement services, expertise in market access, supply chain logistics and unique pharmaceutical finance solutions targeting Life Sciences partners and other industry stakeholders deliver optimal cost savings and improved clinical outcomes. Terebellum’s leadership team has the deep expertise needed to provide a consultative approach to successfully marketing specialty branded products. Visit www.terebellumltd.com
About The Brooks Group
Founded in 1995, The Brooks Group is a highly specialized company focused on increasing the impact of Managed Markets, Sales, Medical and Marketing professionals in the pharmaceutical, biotech, medical device and healthcare industries. We ensure that your customer-facing team has the business skills and market knowledge to proactively access and engage with key stakeholders in the Quintuple Aim era. This provides superior insights, enabling them to build and position the unique value proposition that will mutually benefit your business, patients and customers. www.thebrooksgrouponline.com
About the AscellaHealth family of companies
The AscellaHealth family of companies, consisting of AscellaHealth and its subsidiaries Optime Care and Terebellum, is a global healthcare and specialty pharmaceuticals solutions organization serving specialty and rare diseases, patients, payers, life science manufacturers and suppliers with solutions to the unmet needs in this dynamic market. A unique patient-centric mission and commitment to improved drug access and outcomes are woven into integrated end-to-end solutions spanning the entire pharmaceutical lifecycle and beyond. Visit www.AscellaHealth.com.
Check out the source version at businesswire.com: https://www.businesswire.com/news/home/20220818005073/en/
201.641.1911 x 54
Darcey McDermott, Chief Marketing and Communications Officer
AscellaHealth family of companies